IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02425108.html
   My bibliography  Save this paper

Financialization and productive models in the pharmaceutical industry

Author

Listed:
  • M. Montalban

    (GREThA - Groupe de Recherche en Economie Théorique et Appliquée - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique)

  • Mustafa Erdem Sakinç

    (CEPN - Centre d'Economie de l'Université Paris Nord - UP13 - Université Paris 13 - USPC - Université Sorbonne Paris Cité - CNRS - Centre National de la Recherche Scientifique)

Abstract

This study analyzes the effects of financialization and competition on productive models in major pharmaceutical and biopharmaceutical companies and discusses current theses, which may help explain the transformation of productive models occurring under growing pressure from institutional investors and shareholder value management. We provide evidence of a large dispersion of shareholding and an increase in distribution of shareholder value occurring through large pharmaceutical companies. We show that large pharmaceutical companies have adopted a blockbuster model in an effort to maximize shareholder value, which is explained by various factors including financialization, technical change, product market regulations, and market competition. The stock market is used to make large acquisitions and control the US drug market, creating a growing dependency on stock performance and blockbuster drug sales. We describe how the process of financialization has impacted the biopharmaceutical industry and argue that the blockbuster model as a dominant productive model for the industry since the 1990s is unsustainable. Copyright 2013 The Author 2013. Published by Oxford University Press on behalf of Associazione ICC. All rights reserved., Oxford University Press.
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • M. Montalban & Mustafa Erdem Sakinç, 2013. "Financialization and productive models in the pharmaceutical industry," Post-Print hal-02425108, HAL.
    • Handle: RePEc:hal:journl:hal-02425108
    DOI: 10.1093/icc/dtt023
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Other versions of this item:

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Samuel Klebaner, 2018. "Norm making and institutions dynamics: how the research program of the French Régulation Theory can be fertilized by the methodological concepts from the “Max-Planck-Institute for European Legal Histo," Cahiers du GREThA (2007-2019) 2018-25, Groupe de Recherche en Economie Théorique et Appliquée (GREThA).
    2. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
    3. Rita Vieira & Graça Azevedo & Jonas Oliveira, 2024. "Systematic review in financialization politics: the role of corporate governance and managerial compensation," International Journal of Disclosure and Governance, Palgrave Macmillan, vol. 21(3), pages 376-405, September.
    4. Jan Grumiller & Hannes Grohs & Christian Reiner, 2021. "“Increasing the resilience and security of supply ofproduction post-COVID-19” - The Case of Medical and Pharmaceutical Products," Working Paper Reihe der AK Wien - Materialien zu Wirtschaft und Gesellschaft 216, Kammer für Arbeiter und Angestellte für Wien, Abteilung Wirtschaftswissenschaft und Statistik.
    5. William Lazonick, 2018. "Comments on Gary Pisano: “toward a prescriptive theory of dynamic capabilities”," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 27(6), pages 1165-1174.
    6. Tristan Auvray & Joel Rabinovich, 2019. "The financialisation–offshoring nexus and the capital accumulation of US non-financial firms," Cambridge Journal of Economics, Cambridge Political Economy Society, vol. 43(5), pages 1183-1218.
    7. Philipp A. Thompson, 2019. "Financialization and Institutional Environments," Working Papers hal-02139457, HAL.
    8. Boutillier, Sophie & Laperche, Blandine & Lebert, Didier & Elouaer-Mrizak, Sana, 2023. "A systemic analysis of the technological trajectory at company level based on patent data: The case of Sanofi's vaccine technology," Technovation, Elsevier, vol. 124(C).
    9. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(3), pages 1-14, January.
    10. Klebaner, Samuel & Assogba, Guillaume, 2018. "Quelle cohérence pour la politique française de filières ? Les décalages entre la filière solidaire telle qu’elle devrait être et ce qu’elle est [What Coherence for the French “filières” Policy? Th," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, vol. 23.
    11. Bonizzi, Bruno & Kaltenbrunner, Annina & Powell, Jeffrey, 2019. "Subordinate financialization in emerging capitalist economies," Greenwich Papers in Political Economy 23044, University of Greenwich, Greenwich Political Economy Research Centre.
    12. Fumio Teramae & Tomohiro Makino & Shintaro Sengoku & Yeongjoo Lim & Takashi Natori & Kota Kodama, 2020. "Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth," Sustainability, MDPI, vol. 12(21), pages 1-13, October.
    13. Hahn, Katrin, 2019. "Innovation in times of financialization: Do future-oriented innovation strategies suffer? Examples from German industry," Research Policy, Elsevier, vol. 48(4), pages 923-935.
    14. Nouguez, Etienne, 2020. "How much is your health worth? A research agenda on valuation processes and markets for medicines," economic sociology. perspectives and conversations, Max Planck Institute for the Study of Societies, vol. 21(3), pages 11-19.
    15. Halima Jibril & Annina Kaltenbrunner & Effi Kesidou, 2018. "Financialisation and innovation in emerging economics," FMM Working Paper 27-2018, IMK at the Hans Boeckler Foundation, Macroeconomic Policy Institute.
    16. Enes Işık & Özgür Orhangazi, 2022. "Profitability and drug discovery," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 31(4), pages 891-904.
    17. repec:hal:cepnwp:hal-01492373 is not listed on IDEAS
    18. Ciaran Driver & Maria João Coelho Guedes, 2017. "R&D and CEO departure date: do financial incentives make CEOs more opportunistic?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 26(5), pages 801-820.
    19. Greffion, Jérôme & Breda, Thomas, 2015. "Façonner la prescription, influencer les médecins," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, vol. 17.
    20. Zhang, Haolin & Feng, Yongqi & Wang, Ying & Ni, Juan, 2024. "Peer effects in corporate financialization: The role of Fintech in financial decision making," International Review of Financial Analysis, Elsevier, vol. 94(C).
    21. Niall Reddy & Joel Rabinovich, 2022. "Debunking the short-termist thesis in financialization studies: Evidence from US non-financial corporations 1998 – 2018," Working Papers PKWP2227, Post Keynesian Economics Society (PKES).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02425108. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.